STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and more

The FDA is the U.S. government agency responsible for regulating food, medicines, and medical products. Its work helps oversee products that affect public health. DOGE is the initiative identified in the article with federal workforce cuts. Here, its role matters because those cuts directly affected the FDA.

The article reports that DOGE cuts eliminated 3,500 FDA positions. That reduction came before an even larger staff exodus under former FDA Commissioner Marty Makary. The departures removed experienced workers and institutional knowledge from an agency that depends on specialized expertise.

The source does not provide DOGE’s formal full name or describe its broader structure. It does show its practical effect at the FDA: major staffing reductions, followed by further departures. Three former FDA chiefs said rebuilding the lost institutional knowledge could take years, making the government’s management choices a public-health concern.

The Trump administration changed the FDA through large workforce cuts and a turbulent leadership period. DOGE eliminated 3,500 workers. A larger staff exodus followed under former FDA Commissioner Marty Makary, who resigned in May. These changes affected the agency’s capacity and continuity.

The central concern was not only the number of jobs lost. Departing employees also carried institutional knowledge about the agency’s work. That knowledge includes experience built over time, though the source does not detail particular programs or decisions. Three former FDA chiefs criticized the officials who oversaw the exodus.

Robert Califf, who served under Presidents Obama and Biden, called DOGE one of the biggest disasters in American history. The former chiefs said restoring the agency’s institutional knowledge would take years. Their criticism reflects concern that rapid cuts and leadership turmoil can weaken a specialized regulator beyond the immediate vacancies.

The article gives one firm reduction: DOGE cut 3,500 FDA workers. It also says those cuts preceded a larger staff exodus under former FDA Commissioner Marty Makary. The source does not provide the final number of employees who left or the FDA’s total workforce, so the full percentage impact cannot be calculated.

Even without that percentage, 3,500 departures represent a substantial staffing shock for an agency regulating food, medicines, and medical products. The key issue is experience, not merely headcount. Former FDA chiefs said the exodus robbed the agency of institutional knowledge, meaning accumulated understanding that supports consistent work.

The current reality is therefore larger than the initial figure. The 3,500 cuts were followed by additional departures, and Makary resigned in May. Former leaders said restoring the lost knowledge could take years, suggesting the disruption may outlast the original workforce reduction.

An agency that loses experienced staff may have less institutional knowledge available for reviewing products, monitoring risks, and maintaining consistent decisions. The article does not document specific delayed approvals or safety failures. It does establish why former FDA leaders are worried: the agency lost people who understood its work through experience.

The concrete example is the sequence of 3,500 DOGE cuts followed by a larger staff exodus under Marty Makary. Former FDA chiefs said the departures robbed the agency of institutional knowledge. That knowledge is the practical understanding employees build while carrying out specialized regulatory responsibilities.

The present consequence is a weakened knowledge base rather than a stated list of immediate failures. Robert Califf and two other former chiefs said restoring it could take years. During that rebuilding period, the agency could face greater difficulty sustaining timely approvals, safety oversight, and public-health work, although the source does not quantify those effects.

The delayed rule could prevent Americans from obtaining prescription drugs from licensed international pharmacies. The administration postponed it for 90 days after criticism that the policy could drastically reduce medicine flows from Canada and other countries. The rule was initially scheduled to take effect on October 22.

The practical mechanism is a restriction on how prescription medicines enter the United States through international pharmacies. Patient advocacy groups and dozens of congressional lawmakers urged the administration to rethink the approach. Their concern focused on access: a rule aimed at shipments could also affect people relying on licensed foreign pharmacies.

For now, the delay postpones the rule rather than permanently removing it. The administration is attempting to address illegal goods, especially opioids, entering through low-value foreign shipments. The eventual policy could therefore determine how the government balances enforcement with continued access to medicines from Canada and other countries.

The administration is trying to restrict low-value foreign shipments because it says illegal goods, particularly opioids, enter the United States through them. The shipments also generally avoid tariffs and do not provide data for tracking. That combination makes enforcement harder, according to the policy rationale described in the article.

The mechanism connects two concerns: what packages contain and what information accompanies them. When shippers do not pay tariffs or submit tracking data, authorities have less information about incoming goods. The administration’s delayed rule is intended to address that channel, even though licensed international pharmacies also use foreign shipments.

The policy creates a conflict between enforcement and access. Patient groups and dozens of lawmakers warned that the rule could drastically reduce medicines arriving from Canada and other countries. The 90-day delay gives the administration more time before the measure initially scheduled for October 22 takes effect, but the article does not state its final outcome.

A prescription-drug system has to pursue several goals at once. It must support access to medicines, check product safety, enforce customs rules, and maintain FDA oversight. The article shows these goals colliding when the administration considers restricting foreign shipments while trying to stop illegal goods, particularly opioids.

The key example is the rule initially set for October 22. It could prevent Americans from obtaining prescription drugs from licensed international pharmacies. At the same time, the administration says low-value foreign shipments can carry illegal opioids and often lack tariff payments or tracking data. The same shipment channel can therefore raise both access and enforcement concerns.

The 90-day delay reflects that unresolved balance. Patient advocacy groups and dozens of lawmakers urged reconsideration because medicine flows from Canada and other countries could shrink. Separately, FDA staffing losses may weaken oversight capacity. The article does not explain the system’s detailed legal structure, but it makes clear that access, enforcement, and agency expertise must operate together.